MedTrace Logo

The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye

NCT00705757 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2016-01-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to study changes in skin color that may be caused by using one of the three eye medicines: Xalatan, Travatan or Lumigan.

Conditions

  • Glaucoma
  • Application Site Pigmentation Changes

Interventions

DRUG

latanoprost

Xalatan/latanoprost 0.005% ophthalmic solution one drop qhs for one year

DRUG

bimatoprost

Lumigan/bimatoprost 0.03% ophthalmic solution one drop qhs for one year

DRUG

travoprost

Travatan/travoprost 0.004% ophthalmic solution one drop qhs for one year

Sponsors & Collaborators

  • Summa Health System

    lead OTHER

Principal Investigators

  • Deepak P Edward, MD · Summa Health System

  • Smajo Osmanovic, MD · Arlington eye Associates

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00705757 on ClinicalTrials.gov